Amycretin is Novo Nordisk's investigational unimolecular agonist - a single molecule that activates both the amylin and GLP-1 receptors. Novo is developing it in two formats: a once-daily oral tablet and a once-weekly subcutaneous injection.

How much weight loss did amycretin show?

In a Phase 2 trial in people with type-2 diabetes, once-weekly subcutaneous amycretin produced weight loss of up to about 14.5% versus 2.6% with placebo, and once-daily oral amycretin up to about 10.1% versus 2.5%. Earlier obesity Phase 1 data drew attention for the scale of reduction over a short dosing period.

Why does amycretin matter if CagriSema already combines amylin and GLP-1?

CagriSema combines two separate molecules. Amycretin folds both activities into one molecule, which simplifies formulation and, critically, makes an oral version feasible - something a two-peptide combination cannot easily achieve.

Can you buy amycretin as a research compound?

Amycretin is a proprietary Novo Nordisk molecule and is not catalogued by research-compound suppliers. New-U does not sell amycretin. The established amylin and GLP-1 research references - cagrilintide and semaglutide - are catalogued as lyophilised reference peptides, research use only, not for human consumption.

Shop by goal

Popular compounds

Research resources

Certificates of Analysis

Amycretin: A Research Guide to Novo Nordisk’s Unimolecular Amylin + GLP-1 Agonist

Q: Is amycretin approved?

No. As of mid-2026 amycretin has no marketing authorisation anywhere in the world. It has completed early-phase and Phase 2 trials, with Phase 3 planned. The FDA, MHRA and EMA have not approved it.

Short answer: amycretin is one molecule that does two jobs — a Novo Nordisk unimolecular agonist that activates both the amylin and GLP-1 receptors. Its headline feature is format: Novo is developing it as both a once-daily oral tablet and a once-weekly injection . A Phase 2 trial in type-2 diabetes reported up to ~14.5% weight loss (subcutaneous) and ~10.1% (oral) ; earlier obesity Phase 1 data drew attention for the scale of reduction over a short period. It has no marketing authorisation anywhere as of mid-2026, with Phase 3 planned. New-U does not sell amycretin. Part of our next obesity-research wave overview.

Plain-English summary. Amycretin is an unapproved, investigational Novo Nordisk molecule. The FDA, MHRA and EMA have not authorised it. This page is general information, not legal or medical advice; do not use unapproved compounds on people.

What amycretin actually is

Amycretin is a unimolecular agonist — a single engineered molecule that hits two receptors at once: the amylin receptor and the GLP-1 receptor . That is the same two-pathway idea behind CagriSema, but achieved inside one molecule rather than by combining two. The single-molecule approach is what makes an oral formulation realistic.

The oral-and-injectable story

Novo is developing amycretin in two formats, which is unusual and strategically deliberate:

Once-weekly subcutaneous — the high-efficacy injectable, competing head-to-head with the weekly incretins.

Once-daily oral — a tablet for patients who will not or cannot inject. Oral peptide delivery is hard (peptides are normally digested), so a peptide that survives oral dosing is a meaningful engineering result.

For the broader oral-vs-injectable question across the class, see our explainer on oral vs injectable GLP-1 research.

Why amylin + GLP-1 in one molecule

The two pathways are complementary, not redundant:

GLP-1 receptor — appetite suppression, slowed gastric emptying, glucose-dependent insulin secretion.

Amylin receptor — a distinct satiety signal that appears to restore leptin sensitivity, sharpening the “full” response.

Stacking them in a single molecule means one pharmacokinetic profile to manage instead of two, and one manufacturing stream — a simplification that matters at population scale.

The trial evidence

The subcutaneous Phase 1b/2a results were published in The Lancet (2025). The most concrete efficacy readout to date is the Phase 2 trial in type-2 diabetes (n=448, patients inadequately controlled on metformin with or without an SGLT2 inhibitor):

Formulation Weight loss vs placebo Population Once-weekly subcutaneous up to ~−14.5% (placebo ~−2.6%) Type-2 diabetes Phase 2 Once-daily oral up to ~−10.1% (placebo ~−2.5%) Type-2 diabetes Phase 2

Mean baseline weight in that trial was ~101.1 kg, and HbA1c fell significantly alongside weight. Adverse events were predominantly gastrointestinal and mostly mild-to-moderate, consistent with the incretin and amylin classes. Novo Nordisk has stated it plans to initiate Phase 3 trials across multiple indications.

A note on the numbers. Weight-loss percentages are not comparable across trials with different populations and durations. The diabetes population above typically loses less weight than an obesity-only cohort, so amycretin’s obesity-trial figures may read differently. Treat each number as belonging to its specific trial.

How amycretin compares

Compound Mechanism Format Status Amycretin Amylin + GLP-1 (one molecule) Oral & injectable Phase 3 planned CagriSema Amylin + GLP-1 (two molecules) Injectable NDA filed Petrelintide Amylin only Injectable Phase 3 planned Orforglipron GLP-1 (small molecule) Oral Submissions filed

Amycretin and research compounds

Amycretin is a proprietary Novo Nordisk molecule, not a catalogued reference peptide. New-U does not sell amycretin. The established, verifiable research references covering its two pathways are:

Cagrilintide — the amylin-analogue reference.

Semaglutide — the GLP-1 reference.

Each ships as a sealed, lyophilised reference peptide verified to >99% HPLC purity with a per-batch Certificate of Analysis — research use only, not for human consumption .

Frequently Asked Questions

What is amycretin? A Novo Nordisk unimolecular agonist of the amylin and GLP-1 receptors, in oral and injectable development.

Is amycretin approved? No. As of mid-2026 it has no marketing authorisation; Phase 3 is planned.

How much weight loss? Up to ~14.5% (SC) and ~10.1% (oral) in a Phase 2 diabetes trial; obesity-cohort figures differ.

Why not just use CagriSema? Amycretin packs both activities into one molecule, enabling an oral tablet — a two-peptide combination cannot easily do that.

Can I buy amycretin for research? No — it is proprietary. New-U catalogues the amylin and GLP-1 references (cagrilintide, semaglutide) instead. Research use only.

Primary sources & further reading

The Lancet — Amycretin, a unimolecular GLP-1 and amylin receptor agonist (subcutaneous): Phase 1b/2a (2025)

Novo Nordisk — Amycretin Phase 2 (type-2 diabetes) results

U.S. National Library of Medicine — PubMed: amycretin

ClinicalTrials.gov — amycretin trial registry

U.S. FDA — FDA (no amycretin approval as of publication)

External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way.

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Amylin & GLP-1 References

New-U Research Compounds catalogues cagrilintide and semaglutide — the amylin and GLP-1 research references — as sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Research use only — not for human consumption.

Research-grade · >99% HPLC purity · COA per lot

Buy research peptides from New-U Research Compounds

Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.

Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.

Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.

Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.

Research use only — not for human consumption. All products are supplied strictly for laboratory research purposes.

Amycretin: A Research Guide to Novo Nordisk’s Unimolecular Amylin + GLP-1 Agonist

What amycretin actually is

The oral-and-injectable story

Why amylin + GLP-1 in one molecule

The trial evidence

How amycretin compares

Amycretin and research compounds

Frequently Asked Questions

Related Reading

Primary sources & further reading

From the Lab - Peptides on LinkedIn & Facebook

Lab-Verified Amylin & GLP-1 References

Buy research peptides from New-U Research Compounds

Shop

Learn

Company

Support

Ways to Pay

Shop by Compound

Shop by Goal

Ships worldwide